BMS pulls new diabetes med in Germany

The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.

BI, Lilly go simple in new SGLT med-ed effort

BI, Lilly go simple in new SGLT med-ed effort


Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.